{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:07Z","timestamp":1777387567393,"version":"3.51.4"},"reference-count":60,"publisher":"Elsevier BV","issue":"3-4","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.vph.2013.07.003","type":"journal-article","created":{"date-parts":[[2013,7,18]],"date-time":"2013-07-18T10:15:17Z","timestamp":1374142517000},"page":"53-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?"],"prefix":"10.1016","volume":"59","author":[{"given":"Giulia","family":"Renda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2013.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.vph.2013.07.003_bb0010","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0015","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0020","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0025","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0030","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","volume":"160","author":"Ruff","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0035","first-page":"330","article-title":"Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis","volume":"31","author":"Harenberg","year":"2012","journal-title":"Int Angiol"},{"key":"10.1016\/j.vph.2013.07.003_bb0040","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1160\/TH10-10-0642","article-title":"Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate","volume":"104","author":"Roskell","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1538-7836.2004.01100.x","article-title":"A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial","volume":"3","author":"Eriksson","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0050","series-title":"The dynamics of drug absorption, distribution, action, and elimination","first-page":"1","article-title":"Pharmacokinetics and pharmacodynamics","author":"Buxton","year":"2006"},{"key":"10.1016\/j.vph.2013.07.003_bb0055","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/j.1538-7836.2004.00890.x","article-title":"Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I","volume":"2","author":"Eriksson","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0060","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/dmd.108.023143","article-title":"Apixaban metabolism and pharmacokinetics after oral administration to humans","volume":"37","author":"Raghavan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.vph.2013.07.003_bb0065","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct Factor Xa inhibitor","volume":"71","author":"Camm","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.vph.2013.07.003_bb0070","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/0091270009351883","article-title":"Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers","volume":"50","author":"Ogata","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.vph.2013.07.003_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200847030-00006","article-title":"Population pharmacokinetics and pharmacodynamics of rivaroxaban \u2013 an oral, direct Factor Xa inhibitor \u2013 in patients undergoing major orthopaedic surgery","volume":"47","author":"Mueck","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.vph.2013.07.003_bb0080","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0085","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0090","doi-asserted-by":"crossref","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.vph.2013.07.003_bb0095","doi-asserted-by":"crossref","first-page":"e278S","DOI":"10.1378\/chest.11-2404","article-title":"Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Falck-Ytter","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.vph.2013.07.003_bb0100","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.vph.2013.07.003_bb0105","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.07.003_bb0115","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0120","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1538-7836.2005.01657.x","article-title":"Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement","volume":"4","author":"Eriksson","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0130","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1161\/CIRCULATIONAHA.106.642074","article-title":"A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement","volume":"114","author":"Eriksson","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.07.003_bb0135","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1111\/j.1538-7836.2005.01602.x","article-title":"BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study","volume":"3","author":"Turpie","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0140","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0145","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.07.003_bb0150","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0155","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.07.003_bb0160","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1160\/TH10-09-0601","article-title":"Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies","volume":"105","author":"Turpie","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clpt.2005.06.011","article-title":"Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor","volume":"78","author":"Kubitza","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2013.07.003_bb0170","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.07.003_bb0175","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2008-05-160143","article-title":"A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study","volume":"112","author":"Buller","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vph.2013.07.003_bb0180","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/11595320-000000000-00000","article-title":"Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention","volume":"50","author":"Mueck","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.vph.2013.07.003_bb0185","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0190","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"Buller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0195","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2796.2012.02541.x","article-title":"New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation","volume":"271","author":"Tripodi","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.07.003_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0210","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1111\/j.1538-7836.2007.02764.x","article-title":"The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement","volume":"5","author":"Lassen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0215","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0220","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2013.07.003_bb0230","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.vph.2013.07.003_bb0235","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vph.2013.07.003_bb0240","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0149-2918(01)80109-0","article-title":"A systematic review of the associations between dose regimens and medication compliance","volume":"23","author":"Claxton","year":"2001","journal-title":"Clin Ther"},{"key":"10.1016\/j.vph.2013.07.003_bb0245","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12325-012-0040-x","article-title":"Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients","volume":"29","author":"Laliberte","year":"2012","journal-title":"Adv Ther"},{"key":"10.1016\/j.vph.2013.07.003_bb0250","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1185\/03007995.2012.677419","article-title":"Effect of dosing frequency on chronic cardiovascular disease medication adherence","volume":"28","author":"Coleman","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.vph.2013.07.003_bb0255","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1160\/TH10-01-0066","article-title":"Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation","volume":"104","author":"Weitz","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0260","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/j.1538-7836.2010.04021.x","article-title":"A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty","volume":"8","author":"Fuji","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0265","first-page":"P366","article-title":"Safety and efficacy of edoxaban in patients undergoing hip fracture surgery (abstract)","volume":"37","author":"Fujita","year":"2010","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.vph.2013.07.003_bb0270","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1111\/jth.12230","article-title":"Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials","volume":"11","author":"Raskob","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0275","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1538-7836.2007.02644.x","article-title":"A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0280","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1538-7836.2010.03748.x","article-title":"Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)","volume":"8","author":"Eriksson","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.vph.2013.07.003_bb0285","first-page":"748","article-title":"Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2)","volume":"9","author":"Lip","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.vph.2013.07.003_bb0290","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehr334","article-title":"RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vph.2013.07.003_bb0295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/clpt.2010.106","article-title":"Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose","volume":"88","author":"Leil","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vph.2013.07.003_bb0300","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH11-08-0566","article-title":"Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation","volume":"107","author":"Salazar","year":"2012","journal-title":"Thromb Haemost"}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189113000797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189113000797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T13:27:56Z","timestamp":1539523676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189113000797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":60,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S1537189113000797"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2013.07.003","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The new oral anticoagulants in atrial fibrillation: Once daily or twice daily?","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2013.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}